TDNA - T. Rowe Price Biotech ETF
T. Rowe Price Biotech ETF is an actively managed exchange-traded fund that seeks long-term capital appreciation by investing primarily in biotechnology and life sciences companies. The fund focuses on companies developing innovative therapies, medicines, and technologies across areas such as biotechnology, pharmaceuticals, and medical research.
- Sector
- Financial Services
- Industry
- Asset Management
- Market Cap
- $9.2M
- Beta
- 0.00
- 52-Week Range
- 23.01-25.68
- IPO Date
- Sep 17, 2026
- Exchange
- NASDAQ
TDNA Options Snapshot
Options pricing data for TDNA is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The TDNA overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure.
TDNA fund facts: expense ratio 0.55%, assets under management $9.6M, NAV $23.88 as of the data source's update on Oct 8, 2026, launched Sep 16, 2026, issued by T. Rowe. See the TDNA holdings.
Frequently asked TDNA overview questions
- What is TDNA?
- TDNA is the ticker symbol for T. Rowe Price Biotech ETF, an listed exchange-traded fund. T. Rowe Price Biotech ETF is an actively managed exchange-traded fund that seeks long-term capital appreciation by investing primarily in biotechnology and life sciences companies. Listed on NASDAQ. TDNA is the ETF ticker shown on this page; ETF traders use the fund for diversified exposure to its underlying basket, for sector and factor rotation, and for hedging or replication strategies via the listed options chain.
- What are TDNA's key statistics?
- T. Rowe Price Biotech ETF (TDNA) carries a market capitalization of $9.2M, 52-week range of 23.01-25.68. Full holdings disclosure, expense ratio, and tracking-error history live on the per-ticker fundamentals page or the sponsor's site; daily NAV and premium/discount-to-NAV are accessible from the same view. These structural inputs frame how the ETF options market prices implied volatility relative to its constituents.
- What sector or industry does TDNA belong to?
- T. Rowe Price Biotech ETF operates in the Financial Services sector, in the Asset Management industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare TDNA's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the TDNA data on this page?
- Options snapshots refresh after each trading session; if no snapshot is currently posted for TDNA, it usually reflects low options liquidity or a recently listed name. Fund-level fields (sponsor, expense ratio, holdings concentration where available) refresh from the vendor feed nightly. ETF-specific filings (N-CSR, N-PX, N-CEN) update on the SEC EDGAR cadence. FINRA microstructure data refreshes on the source's cadence; for ETFs the off-exchange volume signal is dominated by authorized-participant creation and redemption rather than directional flow.